

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

| Version of matrix of consultees and commentators reviewed: | | | | | |
|---|--|--------------------------|--|--|--|
| Provisional matrix of consultees and commentators sent for consultation | | | | | |
| Summary of comments, action taken, and justification of action: | | | | | |
| | <i>Proposal:</i> | <i>Proposal made by:</i> | | <i>Action taken:</i> Removed/Added/Not included/Noted | <i>Justification:</i> |
| 1. | <i>No comments were made at consultation</i> | <i>All Stakeholders</i> | | <i>Noted</i> | |
| 2. | <i>Remove British Ethnic Health Awareness Foundation (BEHAF)</i> | <i>NICE Secretariat</i> | | <i>Removed</i> | <i>British Ethnic Health Awareness Foundation (BEHAF) has been removed from the Charity Commission records and therefore doesn't meet the inclusion criteria</i> |

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for appraisal of bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer

Issue date: May 2009

| | | | | |
|----|---|-------------------------|--------------|---|
| 3. | <i>Add National Institute for Health Research</i> | <i>NICE Secretariat</i> | <i>Added</i> | <i>This organisation has been identified and added as a research group.</i> |
|----|---|-------------------------|--------------|---|

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for appraisal of bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer

Issue date: May 2009